Biospecifics Technologies's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Biospecifics Technologies (BSTC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Biospecifics Technologies vs Its Competitors
- TTM: Trailing 12-month revenue of 37M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+23.0% annualized vs trailing 12 months).
- Peer revenue share: Biospecifics Technologies accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BSTC Sales vs. its Competitors, Q3 2020
Biospecifics Technologies generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.1% year over year, combined, vs 19.2% for Biospecifics Technologies. Biospecifics Technologies's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Biospecifics Technologies's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Biospecifics Technologies Corp | Yes | No | No | Yes |
| High-Confidence Competitors (2) | - | |||
| Similar Growth & Profitability (8) | 100.00 % (7 of 7) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BSTC Stock Performance relative to its Competitors
BSTC Stock Performance relative to High-Confidence Competitors
BSTC Stock Performance relative to Similar Growth & Profitability Competitors
Biospecifics Technologies's Competitors Named by the Company
Competitive relationships identified from Biospecifics Technologies reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Carisma Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Biospecifics Technologies's named competitors require a Commercial License.
Methodology: relationships are extracted from Biospecifics Technologies reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.